Iovance Biotherapeutics, Inc.
IOVA
$2.21
$0.083.51%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 175.62% | 636.99% | 11,070.12% | 13,698.99% | 12,751.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 175.62% | 636.99% | 11,070.12% | 13,698.99% | 12,751.20% |
| Cost of Revenue | 155.56% | 287.60% | 777.94% | 975.69% | 1,066.07% |
| Gross Profit | 267.06% | 498.70% | 438.31% | 605.75% | 387.63% |
| SG&A Expenses | 13.18% | 27.88% | 50.05% | 42.92% | 35.49% |
| Depreciation & Amortization | -7.44% | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.06% | 32.55% | 30.28% | 21.14% | 16.50% |
| Operating Income | 4.33% | 10.59% | 14.69% | 14.17% | 3.67% |
| Income Before Tax | 4.28% | 12.63% | 16.70% | 16.20% | 4.27% |
| Income Tax Expenses | 88.66% | 103.20% | 33.33% | 18.71% | -257.27% |
| Earnings from Continuing Operations | 3.02% | 11.43% | 16.52% | 16.18% | 5.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.02% | 11.43% | 16.52% | 16.18% | 5.31% |
| EBIT | 4.33% | 10.59% | 14.69% | 14.17% | 3.67% |
| EBITDA | 5.67% | 12.13% | 17.03% | 17.31% | 6.88% |
| EPS Basic | 19.63% | 27.10% | 32.07% | 31.46% | 28.07% |
| Normalized Basic EPS | 21.42% | 27.81% | 31.92% | 30.90% | 26.80% |
| EPS Diluted | 19.63% | 27.10% | 32.07% | 31.46% | 28.07% |
| Normalized Diluted EPS | 21.42% | 27.81% | 31.92% | 30.90% | 26.80% |
| Average Basic Shares Outstanding | 19.46% | 20.21% | 22.51% | 23.33% | 30.81% |
| Average Diluted Shares Outstanding | 19.46% | 20.21% | 22.51% | 23.33% | 30.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |